Veselka Petrova Dimova-Svetoslavova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Veselka Petrova Dimova-Svetoslavova has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Asma Binte Aziz
International Vaccine Institute , Seoul
1 shared publication - Cathinka Halle Julin
Norwegian Institute of Public Health, NO-0213 Oslo, Norway
1 shared publication - Firdausi Qadri
International Centre for Diarrhoeal Disease Research Bangladesh
1 shared publication - Jennifer Lynn Dembinski
Norwegian Institute of Public Health, NO-0213 Oslo, Norway
1 shared publication - Joakim Øverbø
Norwegian Institute of Public Health, NO-0213 Oslo, Norway
1 shared publication - Kathrine Stene-Johansen
Norwegian Institute of Public Health, NO-0213 Oslo, Norway
1 shared publication
Latest Publications
- Open Access
Cellular and Humoral Immune Profiles After Hepatitis E Vaccination and Infection
Hepatitis E virus (HEV) causes significant morbidity and mortality globally, particularly affecting vulnerable populations such as pregnant women. HEV239 (Hecolin®), a recombinant vaccine containing the immunodominant protruding (E2) domain of the HEV capsid protein, has demonstrated effectiveness, yet detailed human cellular immune responses remain understudied. This study characterized humoral and cellular immune responses following vaccination with HEV239 or natural HEV infection in healthy Bangladeshi women aged 16–39 years. Using dual IFNγ and IL-4 ELISpot assays, we found robust, predominantly Th1-mediated cellular responses at 30 days after the third vaccine dose, comparable to responses during acute infection. Longitudinal antibody assessments confirmed sustained antibody production, primarily against the E2 domain of genotypes 1 and 3, persisting up to two years post-vaccination. Despite limitations related to sample size and assay sensitivity, our findings underscore the immunogenic potential of HEV239 and support a broader use in HEV-endemic regions.
Open AccessCellular and Humoral Immune Profiles After Hepatitis E Vaccination and Infection
Hepatitis E virus (HEV) causes significant morbidity and mortality globally, particularly affecting vulnerable populations such as pregnant women. HEV239 (Hecolin®), a recombinant vaccine containing the immunodominant protruding (E2) domain of the HEV capsid protein, has demonstrated effectiveness, yet detailed human cellular immune responses remain understudied. This study characterized humoral and cellular immune responses following vaccination with HEV239 or natural HEV infection in healthy Bangladeshi women aged 16–39 years. Using dual IFNγ and IL-4 ELISpot assays, we found robust, predominantly Th1-mediated cellular responses at 30 days after the third vaccine dose, comparable to responses during acute infection. Longitudinal antibody assessments confirmed sustained antibody production, primarily against the E2 domain of genotypes 1 and 3, persisting up to two years post-vaccination. Despite limitations related to sample size and assay sensitivity, our findings underscore the immunogenic potential of HEV239 and support a broader use in HEV-endemic regions.